Since the first edition of this book was published, new knowledge has been gained on Vitiligo. This widely revised and updated second edition, written by worldwide experts in the field, fully reflects this progress. The apparently, simple and poorly symptomatic presentation of the disease has been a strong disadvantage to its study, as compared to other common chronic skin disorders such as psoriasis and atopic dermatitis. A good skin-based angle of attack is also lacking because generalized Vitiligo is clearly epitomizing the view of skin diseases as simple targets of a systemic unknown dysregulation (diathesis). This view has mostly restricted Vitiligo to the manifestation of an auto-immune diathesis and skin events, which are easily detected using skin biospies in most other situations, have not been precisely recorded, with the argument that a clinical diagnosis was sufficient for the management of the patient with Vitiligo. This richly illustrated second edition reflects the constant international effort to share the information gathered about this disorder at the clinical, pathophysiological and therapeutic levels. Its aim still being to bridge current knowledge at the clinical and investigative level, to point to the many unsolved issues, and to delineate future priorities for research.
Preface.- I Defining the Disease.- 1.1 historical aspects.- 1.2
definitions and classification.- 1.3 Epidemiology.- 1.4 Histopathology
including electron microscopy.- 1.5 Clinical aspects Including natural
history according to subsets.- Short introduction.- 1.5.1 vitiligo including
acrofacial, universalis.- 1.5.2 segmental vitiligo Including clinical
aspects.- 1.5.3 Mixed vitiligo.- 1.5.4 rare variants including inflammatory.-
1.5.5 subtypes of mucocutaneous pigment cell involvement: mucosal, hair
follicle (leukotrichia), nevus cells (halo nevus).- 1.5.6 extracutaneous
melanocytes.- 1.5.7 Environmental triggers: Koebner phenomenon and
occupational vitiligo.- 1.5.8 associated disorders and comorbidities
includingautoimmune/inflammatory disorders, immunodeficiences, rare monogenic
diseases.- 1.5.9 age and vitiligo: childhood, pregnancy, late-onset.- 1.5.10
vitiligo and skin of colour.- 1.6 assessment and scoring including QoL.- 1.7
Editors synthesis.- II Understanding the Disease.- 2.1 pathophysiology
overview.- Unifying concepts V-SV.- 2.2 methods to study vitiligo.- 2.2.1 in
vivo confocal microscopy and other noninvasive techniques.- 2.2.2 animal
models.- 2.2.3 in vitro.- 2.3 critical assessment of published data on
vitiligo Short introduction.- 2.3.1 Genetics.- 2.3.2 epigenetics.- 2.3.3
melanocyte stability.- 2.3.4 oxidative stress and intrinsic melanocyte
defects.- 2.3.5 immunity (innate, adaptive). Innate and adaptive separated.-
2.3.6 peptides, growth factors including POMC and family.- 2.3.7 Stem cells.-
2.3.8 other defects and mechanisms.- 2.4 pathophysiology of segmental
vitiligo.- 2.5 Editors synthesis.- III Treating the Disease.- 3.1 management
overview.- What has changed in a therapeutic perspective.- 3.2 discussion of
available and new therapies.- 3.2.1 medical therapies.- 3.2.2
phototherapies.- 3.2.3 surgical therapies.- 3.2.4 depigmenting therapies.-
3.3combined/sequential/integrated therapies including maintenance therapy.-
3.4 camouflage.- 3.5 photoprotection.- 3.6 age, gender, ethnic skin, specific
locations.- 3.7 psychological intervention.- 3.8 patients perspectives.- 3.9
discussion of empirical, traditional, alternative approaches.- 3.10
evidence-based medicine perspective and guidelines.- 3.11 beyond guidelines.-
3.12 editors synthesis and perspectives.- Subject Index.
Professor Mauro Picardo graduated in Rome at La Sapienza University, his main topics of interest are skin biochemistry, free radical mediated damage of the skin, mechanism of control of skin pigmentation, and pigmentary disorders. As Director of the Integrated Center of Metabolomic Research (CIRM) at the San Gallicano Institute, he coordinates lipidomic studies on acne and related disorders (seborrheic dermatitis, rosacea) in sebum and blood samples. The team is specialised in vitiligo and in particular in the study of the biological and molecular mechanisms involved in pigmentation with the aim of finding new preventative and therapeutic treatments. Dr Picardo has served in the Board of national and International scientific societies as well as being President of the ESPCR. He chairs the Vitiligo European Task Force and the Pigmentary disorders group of the EADV in collaboration with Dr. Alain Taieb. Professor Picardo has organized several national and international conferences (such as the Vitiligo International Symposium held in Rome in Dec 2016) and is member of the Editorial Board of many dermatological and biochemical journals including Pigment Cell and Melanoma Research and Experimental Dermatology. He is author of more than 300 publications in peer-reviewed journals and more than 30 chapters in different books, most of which are dedicated to pigmentation, focusing on both the biological and clinical approaches.
Alain Taïeb is professor emeritus of Dermatology at Bordeaux University. He established the National Reference Centre for Rare Skin Disorders in 2005. He was until recently Director of INSERM 1035 research lab Biotherapy of genetic diseases, inflammatory disorders and cancer (BMGIC). He set up the European Task Force on Atopic Dermatitis in 1990, and the Vitiligo European Task Force in 2003, which are the current official ad hoc tasks forces of the EADV. He has authored more than 600 articles in peer-reviewed journals and more than 60 chapters in multiauthored books. In addition, he published History of Atopic Dermatitis with Dr Wallach and Tilles, in 2004, and two textbooks Neonatal Dermatology with Drs Enjolras, Wallach and Vabres (2009) and Vitiligo with Dr Picardo (2010- second edition 2019). His major topics of interest are pediatric dermatology, genodermatoses, atopic dermatitis, vitiligo and pigment cell disorders. He has received several awards and distinctions in particular from the Society for Pediatric Dermatology, the European Society of Pediatric Dermatology, the International League of Dermatological Societies, the American Skin Association, and the European Society for Pigment Cell Research. H factor 59 (WoS). Dr Taïeb is currently President of the International Society of Atopic Dermatitis.
Lisainfo e-raamatute kohta